✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
AGN-201904 is an investigational drug.
There have been 58 clinical trials for AGN-201904. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2014.
The most common disease conditions in clinical trials are Presbyopia, Ocular Hypertension, and Keratoconjunctivitis Sicca. The leading clinical trial sponsors are Allergan, Editas Medicine, Inc., and Vitae Pharmaceuticals Inc., an Allergan affiliate.
There are two US patents protecting this investigational drug and forty-three international patents.
Recent Clinical Trials for AGN-201904
|AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients||Milton S. Hershey Medical Center||Phase 1|
|A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines||AbbVie||Phase 1|
|Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia||Allergan||Phase 2|
Top disease conditions for AGN-201904
Top clinical trial sponsors for AGN-201904
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AGN-201904||See Plans and Pricing||Prodrugs of proton pump inhibitors||Winston Pharmaceuticals, Inc. (Newport Beach, CA) The United States of America as represented by the Department of Veteran Affairs (Washington, DC) N/A (Oakland, CA) The Reagents of the University of California (N/A)||See Plans and Pricing|
|AGN-201904||See Plans and Pricing||Process for preparing isomerically pure prodrugs of proton pump inhibitors||Allergan, Inc. (Irvine, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AGN-201904||Argentina||AR042513||2022-07-19||See Plans and Pricing|
|AGN-201904||Austria||AT323695||2022-07-19||See Plans and Pricing|
|AGN-201904||Australia||AU2003259154||2022-07-19||See Plans and Pricing|
|AGN-201904||Brazil||BR0312802||2022-07-19||See Plans and Pricing|
|AGN-201904||Canada||CA2492718||2022-07-19||See Plans and Pricing|
|AGN-201904||Colombia||CO5690576||2022-07-19||See Plans and Pricing|
|AGN-201904||Germany||DE60304726||2022-07-19||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|